RhumbLine Advisers’s CureVac CVAC Stock Holding History

RhumbLine Advisers’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-42,715	Closed	-$838K	–	3129
2022 Q1	$838K	Sell	42,715 -5,054	-11%	-$101K	﹤0.01%	2204
2021 Q4	$1.64M	Buy	47,769 +1,403	+3%	+$56.4K	﹤0.01%	1984
2021 Q3	$2.53M	Sell	46,366 -222	-0.5%	-$13.4K	﹤0.01%	1762
2021 Q2	$3.42M	Buy	+46,588	New	+$4.66M	﹤0.01%	1648

Other funds holding CVAC

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers's CVAC Position: Q2 2022 in Review

RhumbLine Advisers sold out of CureVac (CVAC) in Q2 2022, closing a stake of 42,715 shares — an estimated $838K sold.

RhumbLine Advisers first reported a position in CVAC in Q2 2021 and held it in 4 quarters. The position peaked at $3.42M in Q2 2021. 88 funds tracked by Wall St. Rank hold CVAC as of Q2 2022.

RhumbLine Advisers reported no remaining CureVac position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 42,715 CureVac shares in Q2 2022, an estimated $838K.
RhumbLine Advisers first reported a position in CureVac in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's CureVac position peaked at $3.42M in Q2 2021.
88 funds tracked by Wall St. Rank held CureVac as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.